Frecuencia de uso y costo del tratamiento biológico para enfermedad inflamatoria intestinal y artropatía asociada a enfermedad inflamatoria intestinal en Colombia durante el año 2019

IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY

Revista de Gastroenterologia de Mexico Pub Date : 2024-04-01 DOI:10.1016/j.rgmx.2023.03.007

D.G. Fernández-Ávila , V. Dávila-Ruales

{"title":"Frecuencia de uso y costo del tratamiento biológico para enfermedad inflamatoria intestinal y artropatía asociada a enfermedad inflamatoria intestinal en Colombia durante el año 2019","authors":"D.G. Fernández-Ávila , V. Dávila-Ruales","doi":"10.1016/j.rgmx.2023.03.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and aims</h3><p>Inflammatory bowel disease (IBD) has a high economic burden due to its chronicity. Treatment has evolved, thanks to the understanding of IBD pathogenesis and the advent of biologic therapy, albeit the latter increases direct costs. The aim of the present study was to calculate the total cost and cost per patient/year of biologic therapy for IBD and IBD-associated arthropathy in Colombia.</p></div><div><h3>Methods</h3><p>A descriptive study was conducted. The data were obtained from the Comprehensive Social Protection Information System of the Department of Health for the year 2019, utilizing the medical diagnosis codes of the International Classification of Diseases related to IBD and IBD-associated arthropathy as keywords.</p></div><div><h3>Results</h3><p>The prevalence of IBD and IBD-associated arthropathy was 61 cases per 100,000 inhabitants, with a female-to-male ratio of 1.5:1. Joint involvement was 3%, and 6.3% of the persons with IBD and IBD-associated arthropathy received biologic therapy. Adalimumab was the most widely prescribed biologic drug (49.2%). Biologic therapy had a cost of $15,926,302 USD and the mean cost per patient/year was $18,428 USD. Adalimumab had the highest impact on healthcare resource utilization, with a total cost of $7,672,320 USD. According to subtype, ulcerative colitis had the highest cost ($10,932,489 USD).</p></div><div><h3>Conclusion</h3><p>Biologic therapy is expensive, but its annual cost in Colombia is lower than that of other countries due to the government's regulation of high-cost medications.</p></div>","PeriodicalId":51767,"journal":{"name":"Revista de Gastroenterologia de Mexico","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0375090623000381/pdfft?md5=887755f7e69e7192a02d6f9467fca972&pid=1-s2.0-S0375090623000381-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista de Gastroenterologia de Mexico","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0375090623000381","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction and aims

Inflammatory bowel disease (IBD) has a high economic burden due to its chronicity. Treatment has evolved, thanks to the understanding of IBD pathogenesis and the advent of biologic therapy, albeit the latter increases direct costs. The aim of the present study was to calculate the total cost and cost per patient/year of biologic therapy for IBD and IBD-associated arthropathy in Colombia.

Methods

A descriptive study was conducted. The data were obtained from the Comprehensive Social Protection Information System of the Department of Health for the year 2019, utilizing the medical diagnosis codes of the International Classification of Diseases related to IBD and IBD-associated arthropathy as keywords.

Results

The prevalence of IBD and IBD-associated arthropathy was 61 cases per 100,000 inhabitants, with a female-to-male ratio of 1.5:1. Joint involvement was 3%, and 6.3% of the persons with IBD and IBD-associated arthropathy received biologic therapy. Adalimumab was the most widely prescribed biologic drug (49.2%). Biologic therapy had a cost of $15,926,302 USD and the mean cost per patient/year was $18,428 USD. Adalimumab had the highest impact on healthcare resource utilization, with a total cost of $7,672,320 USD. According to subtype, ulcerative colitis had the highest cost ($10,932,489 USD).

Conclusion

Biologic therapy is expensive, but its annual cost in Colombia is lower than that of other countries due to the government's regulation of high-cost medications.

查看原文本刊更多论文

2019年哥伦比亚炎症性肠病和炎症性肠病相关关节病生物治疗的使用频率和费用

引言和目的炎症性肠病（IBD）因其慢性病而造成了沉重的经济负担。由于对 IBD 发病机制的了解和生物疗法的出现，治疗方法也在不断发展，尽管生物疗法增加了直接成本。本研究旨在计算哥伦比亚 IBD 和 IBD 相关关节病生物疗法的总成本和每位患者/年的成本。数据来自卫生部的社会保护综合信息系统，以《国际疾病分类》中与IBD和IBD相关关节病有关的医疗诊断代码为关键词，获得了2019年的数据。结果IBD和IBD相关关节病的发病率为每10万居民61例，女性与男性的比例为1.5:1。关节受累率为3%，6.3%的IBD和IBD相关关节病患者接受了生物治疗。阿达木单抗是处方量最大的生物制剂药物（49.2%）。生物疗法的费用为15,926,302美元，每位患者每年的平均费用为18,428美元。阿达木单抗对医疗资源利用的影响最大，总成本为7,672,320美元。根据亚型，溃疡性结肠炎的费用最高（10,932,489 美元）。结论生物治疗费用昂贵，但由于政府对高价药物的监管，哥伦比亚的年费用低于其他国家。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista de Gastroenterologia de Mexico GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

1.60

自引率

12.50%

发文量

102

审稿时长

12 weeks

期刊介绍： La Revista de Gastroenterología de México es el órgano oficial de la Asociación Mexicana de Gastroenterología. Sus espacios están abiertos a los miembros de la Asociación como a todo miembro de la comunidad médica que manifieste interés por utilizar este foro para publicar sus trabajos, cumpliendo con las políticas editoriales que a continuación se mencionan. El objetivo principal de la Revista de Gastroenterología de México, es publicar trabajos originales del amplio campo de la gastroenterología, así como proporcionar información actualizada y relevante para el área de la especialidad y áreas afines. Los trabajos científicos incluyen las áreas de Gastroenterología clínica, endoscópica, quirúrgica y pediátrica.

文献相关原料

公司名称	产品信息	采购帮参考价格